NGL Fine Chem Limited, a prominent player in the pharmaceutical manufacturing sector, has announced its unaudited financial results for the first quarter ended June 30, 2025. The company demonstrated robust performance with significant growth in revenue and profitability.

Financial Highlights

• Revenue Surge: NGL Fine-Chem reported consolidated revenue from operations of ₹1,063.57 crore for Q1 FY2026, marking a substantial increase of 18.6% compared to ₹897.00 crore in the same quarter last year.

• Profit Growth: The company's consolidated profit before tax (PBT) stood at ₹1,183.95 crore, showcasing a remarkable year-on-year growth of 1,379.9% from ₹80.00 crore in Q1 FY2025.

• Net Profit Surge: Consolidated profit after tax (PAT) reached ₹924.06 crore, representing an impressive increase of 1,055.1% from ₹80.00 crore in the corresponding quarter of the previous year.

• Earnings Per Share: The basic earnings per share (EPS) on a consolidated basis was reported at ₹29.91.

Standalone Performance

On a standalone basis, NGL Fine-Chem Limited also delivered strong results:

Operational Overview

NGL Fine-Chem Limited continues to operate in the pharmaceuticals manufacturing segment as its primary business focus. The consolidated results include the performance of its wholly-owned subsidiary, Macrotech Polychem Private Limited.

Management Commentary

The Board of Directors, in their meeting held on August 1, 2025, approved these unaudited financial results.

Market Response

Following the announcement, investors and analysts are likely to closely monitor NGL Fine-Chem's stock performance. The significant growth in revenue and profitability may positively impact market sentiment towards the company.

Looking Ahead

As NGL Fine-Chem Limited continues to strengthen its position in the pharmaceutical manufacturing sector, stakeholders will be keen to observe the company's performance in the coming quarters. The impressive start to FY2026 sets a positive tone for the company's growth trajectory in the current fiscal year.

Disclaimer: This article is based on the unaudited financial results announced by NGL Fine-Chem Limited. Investors are advised to conduct their own research and consult financial advisors before making investment decisions.

NGL Fine-Chem , a leading pharmaceutical company, has reported a significant drop in its fourth-quarter consolidated net profit, along with a decrease in revenue. The company has also announced a dividend for its shareholders.

Q4 Financial Performance

NGL Fine-Chem's consolidated net profit for the fourth quarter plummeted to ₹5.40 crore, marking a steep decline from ₹123.20 crore in the same quarter last year. This represents a year-over-year decrease of 95.62%. The company's performance also showed a sequential decline, with profits falling from ₹13.00 crore in the previous quarter.

Revenue for Q4 stood at ₹950.00 crore, down 4.77% from ₹997.60 crore in the corresponding quarter of the previous year. This decline in revenue aligns with the trend observed in the company's recent quarterly performances.

EBITDA and Margin Compression

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q4 was reported at ₹63.00 crore, significantly lower than the ₹158.20 crore recorded in the same quarter last year. This represents a substantial year-over-year decrease of 60.18%.

The EBITDA margin also saw a considerable compression, falling to 6.63% in Q4 from 15.86% in the corresponding quarter of the previous year. This decline in margin indicates increased pressure on the company's operational efficiency and profitability.

Dividend Announcement

Despite the challenging quarter, NGL Fine-Chem has recommended a dividend of ₹1.75 per equity share. This decision to distribute dividends comes as a positive signal to shareholders, despite the company's reduced profitability.

Annual Performance Overview

While the quarterly results show a decline, it's worth noting that NGL Fine-Chem's annual performance for the fiscal year 2024 (ending March 2024) presents a more positive picture:

The annual figures show significant growth across key financial metrics, indicating that despite the weak Q4 performance, the company has managed to improve its overall financial position compared to the previous fiscal year.

Conclusion

NGL Fine-Chem's Q4 results reflect a challenging period for the company, with substantial declines in profit and revenue. However, the annual performance shows resilience and growth. The management's decision to declare a dividend despite the quarterly setback may be seen as a gesture of confidence in the company's long-term prospects. Investors and analysts will likely be watching closely to see how NGL Fine-Chem navigates these challenges and capitalizes on its annual growth momentum in the coming quarters.